Revolution Medicines Pancreatic Cancer Drug Wins FDA Approval, Shares Rise

Revolution Medicines Inc shares rose on Thursday after the company's first-in-class oncology therapy hit the market commercially, prompting multiple Wall Street firms to raise their price targets.

Revolution Medicines stock is gaining positive momentum. What is driving RVMD shares higher?

RVMD Stock Extends Gains on Regulatory Breakthrough

The primary catalyst driving the stock on Thursday was the U.S. Food and Drug Administration's approval on Wednesday of Rasonque for the treatment of adult patients with metastatic pancreatic ductal adenocarcinoma who have received prior systemic therapy or are unable to tolerate multi-agent chemotherapy. Rasonque becomes the first approved targeted therapy among a new class of broad-spectrum RAS-selective inhibitors.

The regulatory approval was supported by data from the pivotal Phase 3 RASolute 302 trial, which showed that Rasonque reduced the risk of death by 60% compared with standard chemotherapy, with median overall survival nearly doubled.

Wall Street Analysts Raise Price Targets After Approval

Following the FDA's decision, several analyst firms raised their price targets on Thursday morning:

Evercore ISI Group: Maintained Outperform rating, raised price target to $320.

HC Wainwright & Co.: Maintained Buy rating, raised price target to $280.

Oppenheimer: Maintained Outperform rating, raised price target to $260.

RBC Capital: Maintained Outperform rating, raised price target to $251.

Truist Securities: Maintained Buy rating, raised price target to $239.

Wedbush: Maintained Outperform rating, raised price target to $225.

Executive Commentary Celebrates Breakthrough Milestone

In Wednesday's press release, CEO and Chairman Dr. Mark A. Goldsmith highlighted the significance of the approval:

"This approval validates more than a decade of work targeting pancreatic cancer—a disease driven largely by RAS and one of the most formidable challenges in medicine, cancer biology, and drug development... We will continue to engage with global regulatory authorities with the goal of expanding and accelerating access to RASONQUE."

RVMD Stock Edges Higher Thursday Morning

RVMD price action: As of Thursday's writing, Revolution Medicines shares were up 1.66% at $219.01. The stock was trading near its 52-week high of $220.34.